Literature DB >> 5795800

A retrospective study of the pharmacokinetics of heparin.

J W Estes, E W Pelikan, E Krüger-Thiemer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5795800     DOI: 10.1002/cpt1969103329

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  9 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

Review 2.  A modern view of pharmacokinetics.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1973-10

3.  The heterogeneity of the anticoagulant response to heparin.

Authors:  J W Estes
Journal:  J Clin Pathol       Date:  1972-01       Impact factor: 3.411

4.  Pharmacokinetic modeling of heparin and its clinical implications.

Authors:  T J McAvoy
Journal:  J Pharmacokinet Biopharm       Date:  1979-08

5.  Interaction of heparin with canine coagulation proteins: in vivo and in vitro studies.

Authors:  P A Gentry
Journal:  Can J Comp Med       Date:  1977-10

6.  Inhibitory effect of heparin on gentamicin concentrations in blood.

Authors:  C Regamey; D Schaberg; W M Kirby
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

Review 7.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

Review 8.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of heparin.

Authors:  J W Estes
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.